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HoOBJECTIVES This study sought to determine the feasibility, safety, and exploratory efﬁcacy of the Embrella Embolic
Deﬂector (EED) system (Edwards Lifesciences, Irvine, California) in patients undergoing transcatheter aortic valve
replacement (TAVR).
BACKGROUND Few data exist on the value of using embolic protection devices during TAVR.
METHODS This pilot study included 52 patients who underwent transfemoral TAVR. The EED system was used in
41 patients, whereas 11 patients underwent TAVR without embolic protection (control group). Cerebral diffusion-
weighted magnetic resonance imaging (DW-MRI) was performed at baseline and within 7 days and 30 days after
TAVR.
RESULTS The EED system was successfully deployed at the level of the aortic arch in all patients with no complications.
The deployment of the EED system was associated with high-intensity transient signals (HITS) as evaluated by trans-
cranial Doppler (median: 48 [interquartile range: 17 to 198] HITS), and a higher total number of HITS was observed in the
EED group (p < 0.001 vs. control group). DW-MRI performed within 7 days after TAVR showed the presence of new
ischemic lesions in all patients in both groups, with a median number of 7 (interquartile range: 3 to 13) lesions per patient.
The use of the EED system was associated with a lower lesion volume compared with the control group (p ¼ 0.003). All
new cerebral lesions had disappeared on the DW-MRI performed at 30 days after TAVR. Two strokes unrelated to the EED
system occurred 2 and 29 days after TAVR.
CONCLUSIONS This study showed the feasibility and safety of using the EED system in TAVR procedures. The EED
system did not prevent the occurrence of cerebral microemboli during TAVR or new transient ischemic lesions as eval-
uated by DW-MRI, but it was associated with a reduction in lesion volume. Further studies are warranted to determine the
efﬁcacy of using the EED system during TAVR procedures. (J Am Coll Cardiol Intv 2014;7:1146–55) © 2014 by the
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AB BR E V I A T I O N S
AND ACRONYM S
DW-MRI = diffusion-weighted
magnetic resonance imaging
EED = Embrella Embolic
Deﬂector
HITS = high-intensity transient
signal(s)
MMSE = Mini-Mental State
Examination
MoCA = Montreal Cognitive
Assessment
NIHSS = National Institutes of
Health Stroke Scale
SWI = susceptibility-weighted
imaging
TAVR = transcatheter aortic
valve replacement
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1147T he occurrence of cerebrovascular ischemicevents remains one of the most worrisomecomplications of transcatheter aortic valve
replacement (TAVR). The periprocedural stroke rate
associated with TAVR is w3% and the PARTNER
(Placement of AoRtic TraNscathetER Valves) trial
showed a higher incidence of early cerebrovascular
events in patients undergoing TAVR compared with
those who received medical treatment or standard
surgical aortic valve replacement (1–3). Furthermore,
several studies have shown a very high incidence
(w70%) of new cerebral ischemic defects as evaluated
by diffusion-weighted magnetic resonance imaging
(DW-MRI) after TAVR (4–8). It is, therefore, of the
utmost clinical importance to implement additional
preventive measures for reducing cerebral emboli
during TAVR procedures.SEE PAGE 1156
TCD = transcranial Doppler
TIA = transient ischemic attackThe use of embolic protection devices in carotid
interventions has been shown to be effective in
reducing the rate of new cerebral ischemic defects as
evaluated by DW-MRI (9), but very few (and pre-
liminary) data are available on the use of embolic
protection devices in the TAVR ﬁeld (1). The Embrella
Embolic Deﬂector (EED) system (Edwards Life-
sciences, Irvine, California) consists of an oval-shaped
nitinol frame covered with a porous polyurethane
membrane that is positioned at the level of the aortic
arch with the purpose of deﬂecting embolic debris
generated during TAVR procedures. Nietlispach et al.
(10) reported the ﬁrst in-human experience with the
EED device showing the feasibility and safety of device
implantation in a preliminary series of 4 patients
(1 aortic valvuloplasty, 3 TAVR procedures). The ob-
jectives of this study were as follows: 1) to determine
the procedural safety, technical feasibility, and
exploratory efﬁcacy of the EED system in patients
undergoing TAVR; and 2) to evaluate the mechanisms
and temporal patterns of embolic events during TAVR
procedures.Krozingen, Germany. The PROTAVI-C Pilot Study was supported by Edwards
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STUDY POPULATION. Patients with severe
symptomatic aortic stenosis considered to
be candidates for TAVR by the heart team at
6 centers in Europe and Canada were
eligible for the study. The study had a
prospective and nonrandomized design that
empirically pre-established the inclusion of
54 patients (9 patients per center), with 42
patients receiving the EED device (the ﬁrst 7
patients at each center) and 12 patients (the
last 2 patients at each center) not receiving
it (control group). The main exclusion
criteria were the following: history of cere-
brovascular event within the previous 12
months, carotid artery stenosis >70%, left
ventricular ejection fraction <20%, serum
creatinine >2.5 mg/dl, known or suspected
right subclavian artery or brachiocephalic ar-
tery stenosis, and any contraindication to undergoing
a DW-MRI examination. The study protocol was
approved by the Ethics Committee of each center, and
all patients had to provide signed informed consent to
participate in the study.
The TAVR procedures were performed according
to the standards of each participating center.
The SAPIEN XT transcatheter valve (Edwards
Lifesciences) implanted via the transfemoral ap-
proach was the only valve/approach permitted.
All patients received dual-antiplatelet treatment
(aspirin þ clopidogrel) before and after the proce-
dure, and intravenous heparin was administered
during the procedure with the goal of obtaining an
activated clotting time of >300 s. All procedural
and 30-day events were deﬁned according to the
Valve Academic Research Consortium criteria (11)
and adjudicated by an independent clinical events
committee.
THE EED SYSTEM. The EED system consists of an
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FIGURE 1 The Embrella Embolic Deﬂector System
(A) The Embrella Embolic Deﬂector system. (B) Angiographic image after deployment
of the Embrella Embolic Deﬂector system at the level of the greater curvature of the
aortic arch.
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114825.5 mm) covered with a porous polyurethane
membrane (100-mm pore size) (Figure 1A). The device
is inserted via the right radial or brachial approach
using a 6-French delivery system. The frame of the
device has 2 opposing petals that are positioned
along the greater curvature of the aorta, covering
the ostia of both the brachiocephalic and the left
common carotid arteries (Figure 1B). The EED system
was to be deployed (as per protocol) at the begin-
ning of the TAVR procedure just before any attempt
to cross the native aortic valve. The system
was retrieved at the end of the procedure and
visually inspected by the physician responsible
for the procedure to evaluate potential tears or
fractures of the nitinol frame and/or polyurethane
membrane.
TRANSCRANIAL DOPPLER EXAMINATIONS. Simultane-
ous Transcranial Doppler (TCD) examinations of
both middle cerebral arteries were performed
during the entire TAVR procedure. Details of TCD
examinations are provided elsewhere (12). All centers
received TCD training and quality supervision by
an expert on TCD (Z.G.), and the same TCD machine
was used at all centers (Multi-Dop T digital system,
DWLCompumedics, Singen, Germany). Time-stamped
signal recording and procedure protocol were used
for ofﬂine analysis to exclude artifacts from patient
movement, catheter ﬂushing, or contrast injections.
The presence and number of high-intensity transient
signals (HITS) at each step of the TAVR procedure were
recorded and measured ofﬂine in a central core labo-
ratory at the Universitäts Klinikum Essen, Essen,
Germany.
CEREBRAL DW-MRI EXAMINATIONS. Cerebral DW-
MRI examinations were performed at baseline(before TAVR) and within 7 days (1 to 7 days) and at
30 days (7 to þ14 days) after the procedure. De-
tails about performing and evaluating cerebral
DW-MRI examinations are provided elsewhere (4).
Brieﬂy, the DW-MRI protocol included 3 sequences:
1) transversal ﬂuid-attenuated inversion recovery;
2) transversal DW-MRI with apparent diffusion
coefﬁcient maps (T2 if susceptibility-weighted im-
aging [SWI] was not available); and 3) transversal
SWI (T2 if SWI was not available). All DW-MRI
exams were analyzed ofﬂine in a central core labo-
ratory at the Universitäts Klinikum of Essen, Essen,
Germany. The presence, number, size, and loca-
tion of all new focal diffusion abnormalities were
evaluated in each patient at the examinations per-
formed within 7 days and at 30 days after the
procedure.
NEUROLOG ICAL AND COGN IT IVE FUNCT ION
ASSESSMENT. Assessment of neurological and
cognitive status was obtained pre-procedure and at
30 days (7 to 14 days) after the procedure. The
following examinations were performed at each time
point: 1) the National Institutes of Health Stroke Scale
(NIHSS) questionnaire (13); 2) the modiﬁed Rankin
Scale score (14); 3) the Barthel Index (15); 4) the Mini-
Mental State Examination (MMSE) (16); and 5) the
Montreal Cognitive Assessment (MoCA) (17). Changes
in neurological (NIHSS, modiﬁed Rankin Scale score,
Barthel Index) and cognitive (MMSE, MoCA) status
over time were determined by changes in the mean/
median values for each test over time.
STATISTICAL ANALYSES. Continuous variables are
expressed as mean  SD or median (25th to 75th
interquartile range) depending on variable distribu-
tion. Comparisons between 2 groups were performed
using the Student t test or Wilcoxon test for contin-
uous variables, and the Fisher exact test for categor-
ical data. Differences were considered statistically
signiﬁcant at p values <0.05. The data were analyzed
with SAS statistical software version 9.1.3 (SAS Insti-
tute, Cary, North Carolina).
RESULTS
A total of 54 patients were included in the study:
42 patients in the EED group and 12 patients in the
control group. One TAVR procedure in each (EED and
control) group was aborted due to failure to obtain
femoral access; those patients were subsequently
excluded from the study, leading to a ﬁnal study
population of 52 patients. The main baseline and
procedural characteristics of the EED and control
groups are shown in Table 1. There were no signiﬁcant
TABLE 1 Clinical and Procedural Characteristics of the Study Population
Variables
EED Group
(n ¼ 41)
Control Group
(n ¼ 11) p Value
Clinical characteristics
Age, yrs 83 (79–86) 84 (78–89) 0.719
Female 22 (53.7) 3 (27.3) 0.177
NYHA functional class III–IV 31 (75.6) 8 (72.7) 0.999
Diabetes 14 (34.1) 5 (45.5) 0.503
Hypertension 36 (87.8) 10 (90.9) 0.999
Coronary artery disease 24 (58.5) 5 (45.5) 0.507
Chronic atrial ﬁbrillation/ﬂutter 4 (9.8) 2 (18.2) 0.595
Carotid disease 6 (14.6) 0 0.322
Peripheral vascular disease 6 (14.6) 1 (9.1) 0.999
Previous stroke/TIA 0 (0) 0 (0) —
COPD 3 (7.3) 3 (27.3) 0.101
eGFR <60 ml/min 18 (43.9) 6 (54.5) 0.735
STS-PROM score, % 5.4 (3.5, 9.3) 6.6 (3.9, 8.0) 0.932
Logistic EuroSCORE 16.1 (10.3–24.0) 18.8 (11.0–28.0) 0.543
Echocardiographic variables
Transaortic gradient, mm Hg 52.4  16.27 44.7  7.59 0.154
Aortic valve area, cm2 0.7  0.15 0.8  0.15 0.056
LVEF, % 57.2  12.88 54.0  9.04 0.279
Procedural variables
Valve size, mm
23 13 (31.7) 0 (0)
26 22 (53.7) 7 (63.6) 0.039
29 6 (14.6) 4 (36.4)
Procedural success 20 (80.0) 8 (100) 0.302
Need for valve-in-valve 0 (0) 0 (0) —
Valve embolization 0 (0) 0 (0) —
Balloon post-dilation 5 (12.2) 3 (27.3) 0.343
EED system
Access
Radial 28 (68.3) — —
Brachial 13 (31.7) — —
Time from access site to deployment (min) 2 (1–3) — —
Successful deployment 41 (100) — —
Repositioning required after initial
deployment
4 (9.8) — —
Device properly seated against aortic arch 41 (100) — —
Device visualized covering both ostia of
brachiocephalic and left common
carotid arteries
40 (97.6) — —
2 devices used 2 (4.9) — —
Device integrity at the end of the
procedure (visual examination)
41 (100) — —
Values are n (%), mean  SD, or median (interquartile range).
COPD ¼ chronic obstructive pulmonary disease; EED ¼ Embrella Embolic Deﬂector (Edwards Lifesciences);
eGFR ¼ estimated glomerular ﬁltration rate; EuroSCORE ¼ European System for Cardiac Operative Risk Evalu-
ation; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; STS-PROM ¼ Society of
Thoracic Surgeons Predicted Risk of Mortality; TIA ¼ transient ischemic attack.
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1149differences in baseline and procedural characteristics
between groups except for transcatheter valve size.
The EED system was successfully deployed at the
level of the greater curvature of the aortic arch in all
patients. The radial approach was the access site in
most (68%) patients, and the median time from
obtaining access to complete deployment of the EED
system was 2 min (interquartile range, 1 to 3 min).
Two devices were used in 2 patients due to excessive
tortuosity of the subclavian artery, which made
advancement and deployment of the ﬁrst device
difﬁcult. Damage of the ﬁrst device was suspected
(but not conﬁrmed after device withdrawal and visual
inspection), and a second device was used. The de-
vice covered both the brachiocephalic trunk and left
carotid artery ostia in all cases but 1 due to anatomic
reasons (anomalous origin of the left carotid artery
from the ascending aorta). There were no cases of
ruptures or tears of the membrane of the device as
evaluated by visual inspection at the end of the
procedure.
The main 30-day events of the study population
are summarized in Table 2. There were 2 complica-
tions related to the EED device: 1 radial thrombosis
with no clinical consequences and 1 pseudoaneurysm
of the brachial artery that required surgical repair.
There were 3 cerebrovascular events (2 strokes, 1
transient ischemic attack [TIA]), all of which occurred
in the EED group, but none of which was related to
the EED system. One patient in whom new-onset
atrial ﬁbrillation developed within the hours after
the procedure had a minor stroke 48 h after the pro-
cedure, and another patient had a major stroke on day
29. One additional patient had a TIA 9 days after the
procedure.
TCD RESULTS. TCD imaging was performed during
the TAVR procedure in all patients, and TCD data
were interpretable in all of them. The results of TCD
examinations in the EED and control groups are
shown in Figure 2. The presence of HITS was
detected at every step of the TAVR procedure in
both groups, and crossing the native aortic valve and
positioning the transcatheter valve were the proce-
dural steps associated with the highest number of
HITS (243 [interquartile range: 124 to 318] HITS
and 87 [interquartile range: 0 to 238] HITS in the
EED and control groups, respectively, p ¼ 0.04),
followed by the deployment of the transcatheter
valve (56 [interquartile range: 18 to 87] HITS and 29
[interquartile range: 0 to 57] HITS in the EED and
control groups, respectively, p ¼ 0.05), and the
insertion of the EED device (48 [interquartile range:
17 to 198] HITS). The total number of HITS duringthe TAVR procedure was higher in the EED group
than in the control group (632 [interquartile range:
347 to 893] HITS vs. 279 [interquartile range: 0 to
505] HITS, p < 0.001).
DW-MRI RESULTS. The timing and patients under-
going DW-MRI examinations at each time point in the
TABLE 2 30-Day Outcomes of the Study Population
Outcome
EED Group
(n ¼ 41)
Control Group
(n ¼ 11) p Value
Stroke 2 (4.9) 0 >0.999
TIA 1 (2.4) 0 >0.999
Major vascular complications 5 (12.2) 1 (9.1) >0.999
Life-threatening bleeding 3 (7.3) 0 >0.999
Renal insufﬁciency/failure 3 (7.3) 0 >0.999
Mortality 3 (7.3) 0 >0.999
Values are n (%).
Abbreviations as in Table 1.
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1150study are shown in Figure 3. The main results of the
DW-MRI examinations performed within 7 days (me-
dian, 3 [interquartile range: 2 to 5] days) after TAVR
are shown in Table 3. All patients (100%) in the 2
groups had new ischemic defects at the ﬁrst DW-MRI
performed after the TAVR procedure. The vast ma-
jority of patients in both groups had multiple defects,
with a median number of defects per patient in the
EED and control groups of 8 (interquartile range: 3 toFIGURE 2 Transcranial Doppler Findings
Transcranial Doppler (TCD) data showing the mean number of high-inte
valve replacement procedure in the Embrella Embolic Deﬂector and con13) and 4 (interquartile range: 2 to 8), respectively,
p ¼ 0.41. No differences (p ¼ 0.58) in total lesion
volume per patient were observed between groups,
but patients in the EED group had a smaller lesion
volume per lesion compared with the control group
(30 [interquartile range: 20 to 50] mm3 vs. 50 [inter-
quartile range: 30 to 70] mm3, p ¼ 0.003).
A total of 31 patients (26 and 5 patients in the EED
and control groups, respectively) had a second DW-
MRI examination performed at 36 (interquartile
range: 29 to 42) days after the procedure. All new ce-
rebral lesions present on the ﬁrst DW-MRI had dis-
appeared in the second DW-MRI (Table 4, Figure 4).
Two patients with cerebrovascular events (1 stroke, 1
TIA) did not undergo DW-MRI at 30 days due to the
implantation of a pacemaker after TAVR. Another
patient had a stroke at day 29 post-TAVR.
The relationship between baseline and procedural
factors and the number and size of new ischemic de-
fects as evaluated by DW-MRI within 7 days after the
procedure are shown in Table 5. A history of peripheral
vascular disease was associated with a higher number
of new ischemic lesions (21 [interquartile range:nsity transient signals (HITS) at each step of the transcatheter aortic
trol groups. THV ¼ transcatheter heart valve.
FIGURE 3 Flowchart for the DW-MRI Examinations
Timing and number of patients undergoing cerebral DW-MRI examinations in the Embrella Embolic Deﬂector and control groups.
DW-MRI ¼ diffusion-weighted magnetic resonance imaging; EED ¼ Embrella Embolic Deﬂector; TAVR ¼ transcatheter aortic valve
replacement.
TABLE 3 DW-MRI Findings After TAVR (Within 7 Days)
EED Group
(n ¼ 34)
Control Group
(n ¼ 6) p Value
Patients with new lesions 34 (100) 6 (100) 0.999
Total no. of new lesions 361 42 —
No. of new lesions per patient 7.5 (3.0–13.0) 4.0 (2.0–8.0) 0.413
Patients with a single lesion 4 (11.8) 1 (16.7) 0.999
Patients with multiple lesions 30 (88.2) 5 (83.3) 0.999
Lesion location
ACA 8 (23.5) 1 (16.7) 0.999
MCA 30 (88.2) 6 (100) 0.54
PCA 22 (64.7) 3 (50.0) 0.999
Cerebellum 23 (67.6) 3 (50.0) 0.999
Border zone 2 (5.9) 0 0.999
Lesion volume, mm3, per lesion 30 (20–50) 50 (30–70) 0.003
Average lesion volume, per patient 43.0 (27.5–85.0) 47.5 (32.5–91.1) 0.583
Total lesion volume, mm3, per patient 305 (130–660) 180 (75–1,115) 0.909
Values are n (%) or median (interquartile range).
ACA ¼ anterior cerebral artery; DW-MRI ¼ diffusion-weighted magnetic resonance imaging; EED ¼ Embrella
Embolic Deﬂector; MCA ¼ middle cerebral artery; PCA ¼ posterior cerebral artery; TAVR ¼ transcatheter aortic
valve replacement.
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115118 to 26] vs. 4 [interquartile range: 2 to 9], p¼ 0.006). A
history of stroke/TIA (p ¼ 0.004) was associated with a
greater lesion volume, whereas the use of the EED
system (p ¼ 0.003) was associated with a lower lesion
volume.
NEUROLOGICAL AND COGNITIVE FUNCTION
ASSESSMENT. The results of neurological and
cognitive function assessment are summarized in
Table 6. Post-procedural neurological evaluation with
the NIHSS scale, the modiﬁed Rankin Scale and the
Barthel Index showed no differences in the median
scores compared with baseline examinations (p > 0.15
for all of them in the EED and control groups). The
post-procedural cognitive assessment with the MMSE
exhibited median values similar to those with the
examinations performed at baseline (p > 0.2 for both
examinations in the EED and control groups). The
cognitive status as evaluated by the MoCA showed a
mild improvement (p < 0.001) at 30 days compared
with baseline in the EED group, and no differences
over time (p ¼ 0.678) in the control group.
DISCUSSION
The present study showed the feasibility and safety of
using the EED system during TAVR procedures. The
device was successfully implanted in all patients,
and the only complications were related to access
site. However, the EED system did not prevent the
occurrence of cerebral microemboli during TAVRprocedures as evaluated by TCD. Indeed, the burden
of procedural cerebral microemboli was higher
compared with patients who had TAVR with no
embolic protection, partially due to the microemboli
occurring during the insertion of the EED system. The
use of the EED system had no effect on the occurrence
and number of new silent cerebral ischemic lesions
as evaluated by DW-MRI within the 7 days after
TAVR. All patients exhibited new ischemic lesions,
TABLE 4 Changes in DW-MRI Findings Over Time (Within 7 Days vs. 30 Days Post-TAVR)
DW-MRI Findings
#7-Day Follow-Up 30-Day Follow-Up
EED
(n ¼ 26)
Control
(n ¼ 5)
EED þ Control
(n ¼ 31)
EED
(n ¼ 26)
Control
(n ¼ 5)
EED þ Control
(n ¼ 31)
Patients with new lesions 26 (100) 5 (100) 31 (100) 0 0 0
No. of new lesions per patient 4.5 (2.0–9.0) 4.0 (4.0–8.0) 4.0 (2.0–9.0) 0 0 0
Patients with a single lesion 4 (15.4) 1 (20.0) 5 (16.1) 0 0 0
Patients with multiple lesions 22 (84.6) 4 (80.0) 26 (83.9) 0 0 0
Values are n (%) or median (interquartile range).
Abbreviations as in Table 3.
FIGURE 4 Cerebra
Cerebral DW-MRI at
and the EED system
lesions in the fronta
the second DW-MRI
as in Figure 3.
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1152which were multiple in the vast majority of
them. However, the volume of cerebral lesions was
smaller in those patients who underwent the
TAVR procedure with the EED system in place. A
history of peripheral vascular disease was the only
factor associated with a higher number, but not vol-
ume, of new cerebral lesions. The occurrence of new
cerebral lesions was not associated with any signiﬁ-
cant early neurological or cognitive impairment, and
all lesions had disappeared at 30 days after the
procedure.
The successful implantation of the EED system in
all patients included in this multicenter study pro-
vides important data on the feasibility of using this
embolic protection system in TAVR procedures.
Indeed, most participating centers had no previous
experience with the device, and the rapidity of
device deployment (median of 2 min after obtaining
access) reﬂects both its simplicity of use and a very
short learning curve. Importantly, there were nol DW-MRI After TAVR
days 3 (A) and 32 (B) after TAVR with a 29-mm SAPIEN XT valve
in an 83-year-old patient. White arrows indicate the new cerebral
l and parietal lobes (A). All new cerebral lesions had disappeared on
post-TAVR (B), only 29 days after the ﬁrst DW-MRI. Abbreviationscomplications related to the deployment of the
device, and no signiﬁcant interaction with the
transcatheter valve system was observed in any case.
In fact, all complications related to the device
occurred at the level of the access site with no major
clinical consequences except for 1 case of brachial
aneurysm that required surgical repair. Also, no sig-
niﬁcant increase in the incidence of acute kidney
injury or new for dialysis was observed in the EED
group compared with the control group or historical
data (18). In addition to the EED system, 2 other
embolic protection devices, the Triguard embolic
deﬂection device (Keystone Heart Inc., Tel Aviv,
Israel) and the Montage dual-ﬁlter system (Claret
Medical Inc., Santa Rosa, California) have reported
feasibility data in patients undergoing TAVR. Also in
accordance with the results of the present study, no
major safety issues were observed with the use of
such devices (19–23).
Previous TAVR studies using TCD monitoring
during the procedure have shown that cerebral
microemboli occur in each of the procedural steps and
are more frequent during valve positioning and
implantation of the transcatheter valve (12,24). In
accordance with these studies, cerebral microemboli
were detected by TCD in all steps of the TAVR pro-
cedure in the present study, and the highest number
was observed during native valve crossing and posi-
tioning of the transcatheter valve system. The use of
the EED system did not prevent the occurrence of
cerebral microemboli in any of the procedural steps,
suggesting that most microemboli occurring during
the TAVR procedure are smaller than 100 mm, which
is the size of the porous membrane of the system.
However, the presence of larger debris (from 0.15 to
4 mm) has also been shown in a recent study using
the Montage dual-ﬁlter device (Claret Medical Inc.)
(21), and these are probably the debris that are
deﬂected by the EED system. Furthermore, although
good apposition of the device against the greater
curvature of the aortic arch was veriﬁed by
TABLE 5 Predictors of Cerebral Lesion Burden as Evaluated by
DW-MRI Within 7 Days Post-TAVR
Variables
Median No.
of Lesions p Value
Median Lesion
Volume, mm3 p Value
Clinical characteristics
Age, yrs
>84 9.0 (4.0–18)
0.091
30 (20–50) 0.308
#84 4.0 (3.0–9.0) 30 (20–80)
Sex
Male 6.5 (2.0–12)
0.662
30 (20–75) 0.192
Female 6.5 (3.0–13) 30 (20–50)
NYHA functional class
I–II 7.0 (2.0–8.0)
0.345
40 (20–90) 0.111
III–IV 6.0 (4.0–18) 30 (20–50)
Diabetes
Yes 5.5 (3.5–9.0)
0.413
30 (20–60) 0.926
No 8.0 (2.5–18.5) 30 (20–50)
Hypertension
Yes 6.5 (2.5–12)
0.402
30 (20–60) 0.171
No 11 (4.0–22) 30 (20–40)
Coronary artery disease
Yes 5.5 (2.0–12)
0.240
30 (20–80) 0.610
No 8.0 (4.0–18) 30 (20–50)
Chronic atrial ﬁbrillation/ﬂutter
Yes 17.5 (8.0–46.5)
0.078
30 (20–40) 0.067
No 5.5 (2.5–10.5) 30 (20–70)
Carotid artery disease
Yes 7.0 (2.0–12)
0.935
30 (15–50) 0.343
No 6.0 (3.0–13) 30 (20–50)
Peripheral vascular disease
Yes 21 (18–26)
0.006
30 (20–40) 0.234
No 4.0 (2.0–9.0) 30 (20–60)
Previous stroke or TIA
Yes 8.0 (1.0–18)
0.721
50 (20–80) 0.004
No 6.0 (4.0–12) 30 (20–50)
eGFR <60 ml/min
Yes 4.0 (2.0–13)
0.796
30 (20–60) 0.739
No 7.0 (4.0–9.0) 30 (20–50)
STS-PROM score (%)
>5.6 6.0 (2.0–17)
0.988
30 (20–50) 0.132
#5.6 6.5 (3.0–9.0) 30 (20–80)
Logistic EuroSCORE
>17.8 10.5 (4.0–19)
0.147
30 (20–60) 0.303
#17.8 4.0 (2.0–8.0) 30 (20–60)
Echocardiographic variables
Mean aortic gradient, mm Hg
>48.0 8.0 (4.0–13)
0.941
30 (20–50) 0.090
#48.0 7.0 (2.0–12) 50 (30–125)
Aortic valve area, cm2/m2
>0.7 5.0 (2.0–12)
0.877
30 (20–50) 0.942
#0.7 8.0 (4.0–13) 30 (20–50)
LVEF, %
>60 5.0 (3.0–9.0)
0.663
35 (25–80) 0.978
#60 8.0 (1.0–18) 40 (20–100)
Continued in the next column
TABLE 5 Continued
Variables
Median No.
of Lesions p Value
Median Lesion
Volume, mm3 p Value
Procedural variables
Balloon post-dilation
Yes 4.0 (4.0–7.0)
0.493
30 (15–60) 0.262
No 8.0 (2.0–13) 30 (20–50)
Use of EED system
Yes 7.5 (3.0–13)
0.413
30 (20–50) 0.003
No 4.0 (2.0–8.0) 50 (30–70)
Values are median (interquartile range).
Abbreviations as in Tables 1 and 3.
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1153angiography at the beginning of the procedure, the
occurrence of cerebral microemboli due to inade-
quate apposition of the device during the procedurecannot be ruled out and should be further evaluated
in future studies. Of note, the deployment of the EED
system was also associated with a signiﬁcant number
of cerebral microemboli. We hypothesize that most
of these microemboli were probably of gaseous
origin, generated during the opening of the device
within the lumen of the aortic arch, but the occur-
rence of solid microemboli due to the interaction of
the device with the wall of the aortic arch cannot
be ruled out. Unfortunately, differentiation between
solid and gaseous microemboli is impossible with
current conventional TCD systems like the one used
in the present study.
TAVR has been systematically associated with a
very high rate (w70%) of new silent cerebral lesions
as evaluated by DW-MRI (Online Table 1) (4–8). The
presence of new lesions is usually multiple, with new
lesions equally distributed in the 2 cerebral hemi-
spheres and vascular territories. The present study
shows that the use of the EED system failed to
reduce the presence and number of new ischemic
lesions compared with a control group and with
historical data. However, the lesion volume was
reduced by about half compared with the control
group and by more than one-half compared with
historical data (Online Table 1). These results are
consistent with those associated with the use of
another embolic deﬂector device, the Triguard device
(Claret Medical Inc.), which also showed a potential
beneﬁcial effect on lesion volume with no effect on
the presence and number of lesions (20). In fact,
lesion volume has been identiﬁed as an important
prognostic factor in patients experiencing a stroke
(25,26), and recent studies have shown that smaller
lesions have a much greater likelihood of being
transient than do larger lesions (27,28). Interest-
ingly, the present study showed for the ﬁrst time
that all new lesions seen on DW-MRI that were
detected within the ﬁrst days after TAVR had dis-
appeared 1 month after the procedure, only about
TABLE 6 Baseline and Post-TAVR Neurological and Cognitive
Function Assessment
Baseline
Evaluation
30-Day
Evaluation p Value
NIHSS
EED group 0 (0–0) 0 (0–0) 0.422
Control group 0 (0–0) 0 (0–0) 0.550
mRS
EED group 0 (0–1) 0 (0–0) 0.291
Control group 0 (0–0) 0 (0–0) 0.343
Barthel Index
EED group 100 (90–100) 100 (95–00) 0.888
Control group 100 (95–100) 100 (100–100) 0.756
MMSE
EED group 28 (26–29) 28 (26–29) 1.0
Control group 27 (21–30) 28 (23–30) 0.186
MoCA
EED group 24 (21–27) 25 (23–28) <0.001
Control group 24 (21–27) 26 (23–27) 0.678
Values are median (interquartile range).
MMSE ¼ Mini-Mental State Examination; MoCA ¼ Montreal Cognitive Assess-
ment; mRS ¼ modiﬁed Rankin Scale; NIHSS ¼ National Institutes of Health Stroke
Scale; other abbreviations as in Tables 1 and 3.
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11544 weeks after the ﬁrst DW-MRI examination. This
is in accordance with the results of the study of
Kahlert et al. (4) showing the disappearance of new
lesions seen on DW-MRI in 80% of the patients at 3
months and is probably related to the very small
size of the vast majority of these new lesions
observed after TAVR.
Whereas the use of the EED device was the pro-
cedural variable associated with a lower lesion vol-
ume as evaluated by DW-MRI, a history of peripheral
vascular disease and stroke/TIA were the baseline
factors associated with a greater number and larger
volume of new cerebral lesions, respectively.
Peripheral vascular disease and previous cerebro-
vascular disease have been associated with a higher
rate of late cerebrovascular events in previous TAVR
studies (29,30), but this is the ﬁrst report high-
lighting the potential role of these factors in cerebral
embolisms occurring early after the procedure. The
presence of these factors usually reﬂects the pres-
ence of a higher atherosclerotic burden including the
ascending aorta/aortic arch, which indeed may
increase the risk of cerebral emboli. In fact, Van
Mieghem et al. (22) showed that atheroma accounted
for a high proportion of the macroscopic debris
captured by a dual carotid ﬁlter device during TAVR
procedures. Finally, it is well-known that only w50%
of cerebrovascular events after TAVR occur within
the 24 h after the procedure (29), and the possibility
of a higher atherosclerotic burden being involved inembolic events in the subacute period (between 24 h
and the time of ﬁrst DW-MRI) after TAVR cannot be
excluded.
Several studies have shown the lack of a rela-
tionship between new cerebral lesions as assessed
by DW-MRI and neurological or cognitive impair-
ment after TAVR (4–8). The patients included in the
present study had an extensive and systematic
evaluation of neurological and cognitive status, and,
as in previous studies, no early deterioration was
detected by these examinations despite the presence
of new cerebral lesions in all of them. The small size
and transient behavior of these new lesions may
partially explain these ﬁndings, but further studies
with a longer follow-up are warranted. The mild
improvement in the MoCA test results observed at
30 days after TAVR in the EED group may be related
to a “learning effect” from the patients fulﬁlling
the test and will have to be conﬁrmed by future
studies.
STUDY LIMITATIONS. Although no major differ-
ences were observed between the control and EED
groups, the results of the comparisons between
groups should be interpreted with caution due to
both the nonrandomized nature of the study and
the small sample size of the control group. These
results need to be conﬁrmed by a larger random-
ized study.
CONCLUSIONS
The use of the EED system in TAVR procedures is
feasible, easy to deploy, and safe, but is associated
with a higher rate of cerebral microemboli as evalu-
ated by TCD. The EED system did not prevent the
occurrence and multiplicity of new cerebral lesions
seen on DW-MRI, but seemed to be associated with
a smaller lesion volume probably related to the
deﬂection of the larger debris, which warrants further
conﬁrmation. Finally, all new lesions seen on the
DW-MRI examination disappeared within a few
weeks and were not associated with any early
neurological or cognitive impairment. While waiting
for the results of future randomized trials, no
recommendation on the systematic use of embolic
protection during TAVR procedures can be made on
the basis of these ﬁndings.
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